Evotec SE Stock (NASDAQ:EVO)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$4.40

52W Range

$2.85 - $12.00

50D Avg

$4.26

200D Avg

$4.80

Market Cap

$1.59B

Avg Vol (3M)

$210.40K

Beta

0.98

Div Yield

-

EVO Company Profile


Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

DE

Employees

5,007

IPO Date

Feb 05, 2004

Website

EVO Performance


EVO Financial Summary


Dec 23Dec 22Dec 21
Revenue$781.43M$751.45M$618.03M
Operating Income$-107.09M$12.49M$27.32M
Net Income$-83.91M$-175.66M$215.51M
EBITDA$-7.16M$94.15M$94.93M
Basic EPS$-0.47$-0.99$1.30
Diluted EPS$-0.47$-0.99$1.29

Fiscal year ends in Dec 23 | Currency in EUR

Latest Earnings Call Transcripts


Q3 24Nov 06, 24 | 7:11 PM
Q2 24Aug 14, 24 | 12:36 PM
Q1 24May 22, 24 | 3:23 PM

Peer Comparison


TickerCompany
PAHCPhibro Animal Health Corporation
NBIXNeurocrine Biosciences, Inc.
SUPNSupernus Pharmaceuticals, Inc.
RDYDr. Reddy's Laboratories Limited
ANIPANI Pharmaceuticals, Inc.
RGCRegencell Bioscience Holdings Limited
PCRXPacira BioSciences, Inc.
PBHPrestige Consumer Healthcare Inc.
COLLCollegium Pharmaceutical, Inc.